77 results
8-K
EX-10.1
BIAF
BioAffinity Technologies Inc
5 Jun 24
Departure of Directors or Certain Officers
4:10pm
of the exercise price and satisfaction of any applicable tax withholding pursuant to Section 16.5, the Company shall deliver to the Participant … . Taxes.
(a) By executing this Grant Agreement, Optionee acknowledges and agrees that Optionee is solely responsible for the satisfaction of any
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
process and requires proof of the safety and effectiveness of the device to the FDA’s satisfaction. As part of the PMA review, the FDA will typically … satisfaction, can subject a manufacturer to warning letters, recalls, or other sanctions and penalties.
Advertising, marketing, and promotional activities
POS AM
EX-5.2
BIAF
BioAffinity Technologies Inc
5 Apr 24
Prospectus update (post-effective amendment)
6:10am
identified to our satisfaction, of (i) the Registration Statement, (ii) resolutions adopted by the Board of Directors of the Company, (iii) the certificate
POS AM
ji4z5lf9uvf9kzqm37
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
8-K
EX-1.1
hb9zmz2sg
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-4.2
p11bo3k
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-4.1
560ydaa72zoxjchla
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-99.1
97x3l4r2w9ekunw4nbqd
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
8nyffxln9v
8 Mar 24
Entry into a Material Definitive Agreement
5:00pm
424B5
7qf5bo3 ruw6cc
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
yjtpt2y
7 Mar 24
Prospectus supplement for primary offering
9:57pm
8-K
EX-99.1
o2vulb3snglminkrkax
5 Mar 24
Increasing physician interest, newly approved reimbursement code driving growth
5:26pm
8-K
kfgmq3mj
31 Jan 24
Departure of Directors or Certain Officers
4:05pm
8-K
EX-10.1
itftk elw0
31 Jan 24
Departure of Directors or Certain Officers
4:05pm